

# Structural basis for the specificity of renin-mediated angiotensinogen cleavage

Yahui Yan<sup>1</sup> (严亚慧), Aiwu Zhou<sup>2\*</sup> (周爱武), Robin W. Carrell<sup>1</sup>, Randy J. Read<sup>1\*</sup>

From the <sup>1</sup>Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 0XY, U.K.; <sup>2</sup>Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao-Tong University School of Medicine, China

Running title: *Specificity of angiotensinogen cleavage by renin*

\*To whom correspondence should be addressed: Randy J. Read: Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 0XY, U.K.; [rjr27@cam.ac.uk](mailto:rjr27@cam.ac.uk); Tel. +44 1223 336500; Fax. +44 1223 336827.

Aiwu Zhou: Hongqiao International Institute of Medicine, Shanghai Jiao-Tong University School of Medicine, China; [aiwu.zhou@googlemail.com](mailto:aiwu.zhou@googlemail.com); Tel. +86 21 63846590-776909; Fax +86 21 64154900.

**Keywords:** renin angiotensin system, serpin, crystal structure, conformational change, site-directed mutagenesis, kinetics, angiotensinogen, proteolysis, aspartic protease, hypertension

---

## Abstract

The renin-angiotensin cascade is a hormone system that regulates blood pressure and fluid balance. Renin-mediated cleavage of the angiotensin I peptide from the N-terminus of angiotensinogen (AGT<sup>1</sup>) is the rate-limiting step of this cascade; however, the detailed molecular mechanism underlying this step is unclear. Here, we solved the crystal structures of glycosylated

human AGT (2.30 Å resolution), its encounter complex with renin (2.55 Å), AGT cleaved in its reactive center loop (RCL; 2.97 Å) and spent AGT from which the N-terminal angiotensin peptide was removed (2.63 Å). These structures revealed that AGT undergoes profound conformational changes and binds renin through a tail-into-mouth allosteric mechanism that inserts the N-terminus into a pocket equivalent to a hormone binding site on other serpins. These changes fully extended the

---

<sup>1</sup>**Abbreviations:** ACE: angiotensin converting enzyme; AGT: angiotensinogen; CBG: corticosteroid-binding globulin; mPEG: methoxypolyethylene glycol; PEI: polyethylenimine; PMSF: phenylmethylsulfonyl fluoride; PNGase F: peptide-N-glycosidase F; RCL:

reactive center loop; rmsd: root-mean-square deviation; S-to-R: stressed-to-relaxed; TBG: thyroxine-binding globulin; TCEP: tris (2-carboxyethyl) phosphine.

N-terminal tail, with the scissile bond for angiotensin release docked in renin's active site. Insertion of the N-terminus into this pocket accompanied a complete unwinding of helix H of AGT, which, in turn, formed key interactions with renin in the complementary binding interface. Mutagenesis and kinetic analyses confirmed that renin-mediated production of angiotensin I is controlled by interactions of amino acid residues and glycan components outside renin's active site cleft. Our findings indicate that AGT adapts unique serpin features for hormone delivery and binds renin through concerted movements in the N-terminal tail and in its main body to modulate angiotensin release. These insights provide a structural basis for the development of agents that attenuate angiotensin release by targeting AGT's hormone binding pocket.

---

## **Introduction**

Human blood pressure is mainly controlled by the renin-angiotensin system, which consists of several key components including renin, angiotensinogen (AGT), angiotensin converting enzyme (ACE) and angiotensin receptors(1). Renin is a highly-specific aspartic protease that cleaves AGT between Leu10 and Val11 to release the N-terminal angiotensin I peptide(1) . This peptide is subsequently processed by ACE to form angiotensin II, which is the major biologically active hormone and functions through binding to its receptors. Cleavage of AGT by renin is the rate-limiting step of the renin-angiotensin system(2) . This step is tightly regulated in mammals to maintain normal blood pressure, with subtle changes often associated with hypertension and other cardiovascular diseases. For example, a mild increase (10-20%) in plasma concentrations of

human AGT caused by the Met235Thr polymorphism is often associated with essential hypertension(3)(4). Also, an AGT mutation where Leu10 is replaced by a Phe, resulting in a mere 2-fold increase in the cleavage efficiency of the mutant by renin, is associated with the development of preeclampsia, a life-threatening hypertensive disorder during pregnancy(5).

Previous structural and biochemical studies of renin-AGT interactions have revealed that renin specifically recognizes and cleaves the N-terminal tetradecapeptide of AGT, the only known natural substrate of renin. It has also been shown that the body of the AGT molecule is critical for efficient angiotensin I release by renin, as the  $K_M$  value for AGT is 10-fold lower than that of a synthetic 14-residue peptide derived from the AGT N-terminus(6, 7). Our previous structural characterizations of AGT and renin have shown that AGT adopts the typical serpin (serine protease inhibitor) framework with a central beta-sheet and a surface-exposed reactive loop, and that binding of AGT by renin induces substantial movements of both a surface loop and the N-terminal tail, linked by a labile disulfide bond(8). However due to limited resolution (4.35 Å) of the AGT/renin complex structure, the detailed molecular interactions between AGT and renin remain obscure. Furthermore, human plasma AGT is a heterogeneous glycoprotein resulting from its variable glycosylation. One of the glycosylation sites at Asn14 is close to the scissile bond (Leu10-Val11) and has been shown to affect the efficiency of angiotensin I release(9, 10). It is unclear how the presence of carbohydrate at the glycosylation sites would affect the conformation and activity of AGT.

To address these questions, here we have solved high-resolution crystal structures of human

glycosylated AGT, its encounter complex with renin, AGT cleaved in the reactive center loop, and the spent AGT from which the N-terminal angiotensin peptide has been removed by renin. These structures together with detailed biochemical characterizations revealed that, when renin binds AGT, the N-terminal angiotensin tail is inserted into a pocket on AGT that is a hormone-binding site in other serpins. This and other binding interactions induce profound conformational changes in AGT.

## Results

### **Crystal structures of human glycosylated AGT, its complex with renin, loop-cleaved AGT and spent AGT**

In order to understand how renin binds AGT and how glycosylation affects their interaction, here we have prepared glycosylated human AGT variants (Asn137/271/295Gln, Cys232/308Ser, termed AGT-N14) where only a single glycosylation site on Asn14 is retained. Subsequently we prepared spent AGT where the N-terminal 10-residue angiotensin I peptide was removed from the AGT-N14 expression construct and AGT-N14 cleaved between Gln412 and Leu413 by thermolysin treatment. An inactive human renin variant (Asp226Ala) was also prepared from HEK293 cells for crystallizing the encounter complex of renin and AGT. The structures of AGT, its complex with renin, the spent AGT and RCL-cleaved AGT were solved at 2.3 Å, 2.55 Å, 2.6 Å, and 2.97 Å resolution respectively. All structures were refined to good geometry with statistics shown in Table 1.

### **The N-terminal tail is sequestered in native AGT**

The crystal structure of AGT-N14 shows that

AGT retains a typical serpin fold with the extra 63-residue extension at the N-terminus being well ordered, similar to the previous unglycosylated AGT structures(8). The conserved disulfide bond between Cys18 and Cys138 is properly formed and the N-terminal tail residues form extensive hydrophobic interactions and several hydrogen bonds with the body of AGT (Figure 1A, B). Residues Ile5, Phe8, Leu10, Val11 and Ile12 pack with residues (Leu66, Met72, Leu76 and Phe79) from helix A and residues (Val131, Trp133 Val142, Val147) from the CD loop (loop connecting helices C and D) and helix D. This leads to the scissile bond of Leu10-Val11 being buried in an inaccessible position (Figure 1C). The potential drawback of this configuration is that AGT has to undergo conformational changes for the scissile bond to move out to bind renin, while the advantage is that it could protect the scissile bond from non-specific cleavage by other proteases.

### **The binding interactions between renin and AGT**

The crystal structure of the AGT-renin complex shows that the N-terminal tail of AGT is docked in the substrate-binding pocket of renin (Figure 2). The total surface area buried in the interface between AGT and renin is more than 2100 Å<sup>2</sup>: interactions between the N-terminal peptide and the renin active site account for about 50% of the buried surface while interactions between the bodies of AGT and renin account for the rest. Renin is an aspartic protease in which the active site is formed by the junction of two similar domains, each containing an aspartic acid residue (Asp38 and Asp226 in human renin) to form a catalytic dyad that hydrolyzes the peptide bond(11). Although the Asp226 of renin was mutated to alanine to obtain a stable initiation complex, the binding interactions within the renin

active site largely resemble those seen in the crystal structure of a renin-peptide complex solved previously (PDB 1SMR)(12). The Asp38 of renin is hydrogen bonded to the carbonyl oxygen of the scissile bond and to a water molecule that is also within hydrogen bond distance to the other mutated aspartic acid (Figure 3A). Therefore, the active site conformation in our structure is consistent with the well-accepted proposal(13) that Asp38 protonates the carbonyl oxygen of the scissile bond of the natural protein substrate, while the Asp226 carboxyl is ionized and deprotonates the catalytic water molecule that initially bridges the two aspartates. One of the imidazole nitrogens (NE2) of His9 is hydrogen-bonded to the O<sub>γ</sub> of Ser233, whereas the other nitrogen (ND1) connects His13 through a bridging water (Figure 3B). Neither His9 nor His13 are connected to the catalytic dyad directly or indirectly. Therefore, it is unlikely that the peak at the slightly acidic pH 6.5 in the pH activity profile for the cleavage of AGT by human renin is solely determined by the histidines around the scissile bond(12, 14, 15). The hydrogen bond network Trp45-Tyr83-water-Ser41-Asp38 is also present, connecting the N-flap of renin with the catalytic site (Figure 3A). Such a network is conserved in aspartic proteases and has been shown to be essential for renin activity(16). However there are subtle difference in the renin conformations between the complexes. The N-flap of renin in the renin-AGT complex is in a relatively open conformation with the tip of the flap shifted by about 5 Å when compared to that seen in the renin-peptide complex (Figure 3D). This is likely induced by the longer N-terminal tail of AGT, which holds renin against the body of AGT. In addition to the essential hydrogen bonds around the active site, hydrophobic interactions account for the complementary steric fitting of the

peptide in the renin binding pocket. There are four main subsites: S3, S1, S1' and S2' (according to the nomenclature of Schechter and Berger(17)), accommodating Phe8, Leu10, Val11 and Ile12 of the peptide (Figure 3C). It has been suggested that the sizes and shapes of these binding pockets partly determine the species specificity of the action of renin on AGT(12).

The substantial interactions between the bodies of the two molecules are mainly hydrophobic (Figure 4A, B). The surface of AGT involved in binding renin includes residues from helix H, helix A, helix C, the CD-loop and the IJ-loop (loop connecting helices I and J). Helix A of AGT lies across the binding interface with side chains of six hydrophobic residues (Leu68, Ala71, Met72, Met75, Leu76 and Phe79) facing towards renin and stacking with Ala116, Leu117, Met120, Leu121, Leu252 and Phe253 of renin (Figure 4B). Residues in helix C (Ala127 and Ile128) and in the IJ-loop (Leu368, Pro369 and Ile371) also form hydrophobic interactions with renin residues Leu54 and Tyr55. There are also several hydrogen bonds between the bodies of the two molecules (Figure 4C). Arg83 of AGT forms a cluster of hydrogen bonds with renin residues (Arg53, Leu54, Thr56). Asn331 and Asn334 in the unwound helix H form hydrogen bonds with Tyr60 and Tyr15 of renin, respectively. Arg53 in renin forms a salt bridge with Glu367 and a cluster of hydrogen bonds with the main chain of the IJ-loop in AGT.

It has been well documented that human renin cannot efficiently process AGT from mouse and rat(18–20). A sequence alignment shows that, of the interacting residues, Arg83, Asn331 and Asn334 are not strictly conserved among species. To assess the importance of these residues in AGT, we prepared AGT mutants in which Arg83,

Asn331 and Asn334 were replaced with the corresponding residues from rat, mouse and sheep AGT and assessed their binding affinity and catalytic efficiency towards human renin (Figure 4D, Table 2 and Figure S-1). The Asn334Thr mutation did not significantly affect either the binding affinity or the catalytic efficiency. The catalytic efficiency for cleavage of AGT Arg83His was about half that of the wild type, and the binding affinity was 2.2-fold lower. Most significantly, the binding affinity of the Asn331Asp variant decreased about 4.6-fold with the consequence of a 5-fold decrease in the catalytic release of angiotensin I. This indicates that residues involved in the body-to-body interface between AGT and renin play a key role in determining the catalytic efficiency and binding affinity of renin. This explains the species specificity of human renin towards AGT from other mammals and also explains why intact AGT has a 10-fold lower  $K_M$  value compared to the tetradecapeptide derived from its N-terminus(6, 7).

To further characterize the binding interactions between the bodies of AGT and renin, we prepared spent AGT where the angiotensin peptide is removed by renin, measured its binding affinity towards renin and tested its effect on renin cleavage of intact AGT. One might expect spent AGT to have modest binding affinity towards renin as the binding interface between the bodies of two molecules covers more than  $1000\text{\AA}^2$  buried surface, however we found spent glycosylated AGT cannot form a stable complex with renin when analyzed by gel filtration or native PAGE (data not shown). The binding affinity derived from steady state analysis gives a  $K_D$  value of  $13\mu\text{M}$  (Figure S-2) which is 640-fold weaker than the binding of intact AGT to renin. We then tested if spent AGT could interfere with the interaction

between renin and intact AGT through a product inhibition effect. As shown in Figure S-3, renin readily cleaves an AGT fusion protein to generate spent AGT. When increasing amounts of spent AGT were added, substantial inhibition arose at a concentration of  $0.65\mu\text{M}$  spent AGT (Figure S-3, lane 5), which is about half the concentration of intact AGT in the assay ( $1.1\mu\text{M}$ ). As a negative control, the addition of another serpin, protein Z-dependent inhibitor, had no effect on renin cleavage of AGT. The concentration of circulating intact AGT in plasma of normotensive subjects is about  $1.1\mu\text{M}$  and the spent AGT appears to be far lower(21, 22). Even though the relative abundance of spent AGT versus intact AGT increases in plasma in some pathologic states when renin secretion is stimulated(21), it is still highly unlikely that the spent AGT concentration could be on the same level as the intact AGT. Therefore, we conclude that spent AGT does have a product inhibition effect on renin cleavage of intact AGT; however, it is unlikely to be significant in vivo. It appears that the optimal binding affinity between the bodies of AGT and renin has been selected to enhance the activity of renin and at the same time to avoid significant product inhibition under physiological conditions. The lack of ordered structure for residues 16-28 near the N-terminus or for residues 132-141 in the CD-loop in bound AGT may be relevant; if these residues were well-ordered, they would be positioned to interact with the N-flap of renin, which could increase binding affinity beyond the optimal range.

### **Conformational changes of human AGT induced by renin binding**

Comparison of structures of native AGT and its complex with renin shows that the N-terminal tail of AGT undergoes significant conformational changes to dock into the substrate binding site of

renin with the scissile bond presented appropriately for hydrolysis by the two active aspartate residues (Figure 5A, B). In native AGT, the region of the N-terminal tail near the scissile bond Leu10-Val11 forms hydrophobic interactions with helix A residues such as Leu68, Met72, Leu76 and Phe79 (Figure 1C). These interactions are lost on binding to renin, when the scissile bond shifts about 19 Å from its sequestered position to an extended configuration (Figures 5A and 5B), but are replaced by new interactions with renin residues such as Leu117, Leu121, Leu252 and Phe253 (Figure 4B). Complex formation is also associated with secondary structural changes in other areas of AGT. Notably, helix A is extended by nearly 2 turns and bent towards the core of AGT, with the side chain of Trp92 at the C-terminal part of helix A flipping out to allow space (Figure 5C). Minor conformational changes around helices I and J are also likely induced by renin binding.

Most unexpectedly, we have found that the N-terminus of AGT emerges from the renin active cleft and pokes into a surface cavity surrounded by helix H, sheet B and helix A of AGT (Figures 6A and 6B). This cavity corresponds to the hormone binding pocket seen in two other serpins, thyroxine-binding globulin (TBG; Figure 6C) and cortisol-binding globulin (CBG)(23). The side chain of Arg2 of the N-terminus is completely buried in the relatively shallow pocket and is stabilized by hydrogen bonds with neighboring residue Gln300 (Figure 6A). The side chain of Val3 interacts with hydrophobic residues within this hormone binding pocket, including Met336. The entire helix H (residues 330-336) is unwound, with the shift of residues 333-337 opening up the pocket to accommodate the N-terminal tail and with Asn331 and Asn334 shifting to form key hydrogen bonds with the body of renin (Figure 4C

and 5C, Table 2). At the same time, helix G is extended by a half turn. AGT appears to have adopted a “tail-in-mouth” mechanism for interacting with renin, where insertion of its N-terminus into the hormone binding pocket helps to stabilize a new conformation that forms a complementary surface on AGT for renin binding. It is tempting to speculate that any ligands that bind tightly to this pocket in intact AGT would attenuate the interaction between AGT and renin and have an anti-hypertensive effect.

To further dissect the conformational plasticity of AGT, we then solved the crystal structure of spent AGT and compared it with that of intact AGT. The spent AGT retains a similar fold to native AGT with an rmsd of 0.63 Å over 355 C $\alpha$  atoms (Figure 5D). Helices A, I and J of spent AGT, which are involved in renin binding, have the same conformation as in native AGT. Hence, it is possible that the native and spent AGT have similar angiotensin I independent functions through hypothetical receptors to the same serpin characteristic binding sites(24, 25). In contrast, there are significant movements in the CD-loop. To some extent this may reflect flexibility in this part of the molecule, influenced by different crystal packing environments: the CD-loop is involved in packing interactions in the crystals of both intact and spent AGT. However, it is notable that the rearrangement of the CD-loop in spent AGT places the side chain of Trp133 in the hydrophobic pocket occupied by the scissile peptide region in intact AGT, replacing the side chain of Val11. Finally, helix H in the spent human AGT is disordered with no clear electron density while it is in a helical conformation in intact AGT. This may also be influenced by crystal packing; if helix H in spent AGT were ordered in the same conformation as in intact AGT, it would clash with

the CD-loop of a neighboring molecule. The lability of helix H in human AGT is reminiscent of the rat and mouse AGT structures (PDB 2WXX, 2WXY, 2WXZ, 2WY0 and 2WY1), in all of which helix H exists in an unwound or slightly distorted conformation. It is plausible that helix H of AGT is inherently unstable and can equilibrate between both conformations, only forming favorable interactions with renin when induced by the insertion of the N-terminus of AGT in the hormone binding pocket. A reduced stability of helix H in spent AGT could partly explain why spent AGT only has a relatively low binding affinity towards renin (Figure S-2).

To confirm conclusions from biochemical experiments that cleavage of the reactive center loop of AGT does not trigger the S to R transition characteristic of inhibitory serpins, we solved the structure of AGT cleaved by thermolysin treatment and compared it with that of intact AGT. Loop cleavage indeed induces no significant conformational changes, with an rmsd of only 0.28 Å over 371 C $\alpha$  atoms (Figure S-4). The cleaved loop is disordered but is not inserted into the central  $\beta$ -sheet A.

### **Glycosylation effect on AGT**

It has been demonstrated that glycosylation of human AGT is not crucial for its intracellular trafficking and secretion, but it does play an important role in affecting the interactions between AGT and renin with altered enzyme kinetic parameters(9). Notably, unglycosylated AGT is a better substrate than glycosylated AGT for renin cleavage, and the carbohydrate at glycosylation site Asn14 seems to play a key role in affecting renin activity(5, 22) It is further confirmed here that both the quadruple glycosylation mutant N14/137/271/295Q, termed

N4, where all four glycosylation sites were mutated, and the AGT N14Q variant can be processed by renin about 2.5-fold faster than the fully glycosylated wild type AGT (Table 2). Here in our crystal structures, glycans linked to glycosylation site Asn14 could be resolved with clear electron density (Figures S-5). In the native AGT structure, the oligosaccharide attached to Asn14 forms several stabilizing hydrogen bonds to the surrounding residues of AGT (Lys146, Ser16 and Thr17) (Figure S-5A), while in the complex structure, the carbohydrates make no direct contacts with neighboring renin residues (Figure S-5B). As the C $\alpha$  atom of Asn14 shifts about 16 Å upon complex formation, it is likely that shifting the bulky carbohydrates linked to Asn14 and breaking their hydrogen bonds during renin binding contribute to the lower efficiency of renin in processing glycosylated AGT. Thus this glycosylation at Asn14 probably also contributes to the well-known observation that human AGT can only be efficiently cleaved by primate renin but not by renins from non-primates that lack Asn14 in their copies of AGT(9, 10, 26).

## **Discussion**

The serpin superfamily is classically characterized by proteins that fold into a conserved metastable tertiary structure that has the ability to undergo profound conformational changes for protease inhibition. However, three members of this superfamily, TBG, CBG and AGT, have lost the ability to inhibit proteases and become hormone carriers instead. TBG and CBG are close homologues, with thyroxine and cortisol binding to equivalent pockets on the serpin framework, formed by helices H and A and strands 3-5 of the B-sheet(23, 27, 28). Thyroxine and cortisol release are triggered by a conformational

S-to-R (stressed-to-relaxed) transition similar to that seen in inhibitory serpins. In contrast, it has been shown that AGT has lost the ability to undergo this typical serpin S-to-R transition(29), confirmed here by our structure of loop-cleaved AGT, so it was very puzzling why the serpin framework was selected in the course of evolution as an angiotensin carrier. Does the serpin structure of AGT merely provide a carrier for the added-on tail? One part of the answer may be that AGT was originally a bifunctional protein serving both as a protease inhibitor and the donor of a peptide hormone, which still seems to be the case in the lamprey(30–32).

Here we have addressed this puzzle by solving the structures of glycosylated AGT and its complex with renin. This reveals for the first time the extensive hydrophobic interactions and hydrogen bonds in the renin active site and in the interface between the two components. Renin binding of AGT requires substantial conformational changes in the N-terminal tail of AGT, in which the scissile peptide of angiotensin is expelled from a sequestered position to dock into the active site pocket of renin. This mode of renin binding is likely achieved through competition between the N-terminal tail of AGT and the body of renin for binding to helix A of AGT. Most remarkably we found that the N-terminus of AGT inserts into the equivalent of the hormone-binding pocket seen in TBG and CBG. This insertion is accompanied by the unwinding of helix H, which we know from structures of rat and mouse AGT to be inherently unstable; this unwinding allows residues such as Asn331 and Asn334 to form critical interactions with renin. The conformational change shifts the C $\alpha$  atom of Asn331 by more than 6 Å during complex formation. Substituting this residue with the

corresponding Asp331 seen in mouse or rat AGT results in a 5-fold decrease in catalytic efficiency of renin cleavage (Table 2), consistent with the finding that human renin cleaves mouse and rat AGT with significantly lower catalytic efficiency than human substrate. Thus, renin binding of AGT induces concerted movements in angiotensin including expulsion of the N-terminal tail from a sequestered position, docking into the renin active site, insertion of the N-terminus into the hormone binding pocket, unwinding of helix H and subsequent extension of helix G, all of which ultimately leads to a complementary binding interface between the bodies of AGT and renin. Altogether this further supports the idea that AGT is not just a passive carrier of an angiotensin peptide and that sophisticated use is made of its serpin framework, especially its “hormone binding” pocket, in the efficient release of angiotensin by renin cleavage.

The serpin framework, like many other protein scaffolds, is also subject to post-translational modifications such as oxidation or glycosylation, and these modifications can have significant effects on activity or conformation. For example, the activity of SerpinB9, a regulator of the cytotoxic lymphocyte granzyme B, is reversibly inhibited by vicinal disulfide bond formation in the reactive loop(33). In our previous study, we revealed that AGT has a conserved, labile disulfide bond between Cys18 and Cys138 and that oxidized AGT is a better substrate than the reduced form for renin cleavage. Most intriguingly it was found that an increased ratio of oxidized AGT over the reduced form in plasma is associated with preeclampsia, a hypertensive disease during pregnancy(8). This finding has now been confirmed by an independent large case-control study in patients with preeclampsia using

an improved ELISA method(34).

Serpin activity can also be modulated by glycosylation. For example, the carbohydrate linked to Asn135 in antithrombin can affect heparin binding, with fully glycosylated antithrombin (the alpha form) having lower affinity(35). Glycans linked to Asn347 in the reactive center loop of CBG also retard proteolysis and subsequent cortisol release(36). Similarly, the presence in AGT of glycans linked to Asn14 decrease angiotensin I release by renin cleavage. We speculate that the heterogeneity of glycosylation at this site could serve as an additional control point to modulate angiotensin I release, in the same way that variable glycosylation affects the rate of activation of plasminogen by tissue-type plasminogen activator(37).

As the human renin-angiotensin system differs significantly from those of other species(38) and many residues in the renin-AGT interface are not conserved, we have looked for polymorphisms of these residues. A recent analysis of exome sequences in over 60,000 individuals, carried out by the Exome Aggregation Consortium(39) allows polymorphisms to be detected at much lower frequency in the human population than previously possible. The database reveals that some mutations in residues that interact in the complex between AGT and renin do occur at low frequency. In AGT, an Arg83His substitution is seen twice in 121400 sequence reads (a frequency of  $1.65 \times 10^{-5}$ ); we have shown that this substitution would reduce catalytic efficiency by a factor of 2 (Figure S-1, Table 2). An Arg83Cys substitution occurs at the same frequency, and Arg83Leu at a frequency of only one in 121400 ( $8.24 \times 10^{-6}$ ). Polymorphisms are also found for two of the renin residues that contact Arg83 in AGT (Figure 4C,

Table 2). The substitution Arg53His is seen at a frequency of  $3.88 \times 10^{-5}$  and Arg53Cys at a frequency of  $1.4 \times 10^{-5}$ . Perhaps the most interesting polymorphism is a Cys18Arg substitution in AGT, which occurs at a frequency of  $1.95 \times 10^{-3}$ , a level at which about one in 250 individuals should be heterozygous. It seems likely that the Cys18Arg variant would behave in the same way as reduced wild-type AGT, resulting in a lowered response to the effects of oxidative stress(8) and a somewhat reduced response to triggers of the RAS. It would be intriguing to learn whether individuals carrying at least one copy of this polymorphism have reduced risks of cardiovascular complications, such as hypertension or preeclampsia, or whether it is disadvantageous under any circumstances.

Overall our findings indicate that, over the course of evolution, AGT has retained many features found in other serpins, adapting them to modulate angiotensin release by renin cleavage. AGT binds renin through a concerted tail-in-mouth movement using a site that binds hormones in other serpins; this contributes to the unwinding of helix H of AGT when forming key interactions with renin in the complementary binding interface. This new understanding of the interaction of renin and AGT provides the basis for the development of new agents to attenuate angiotensin release through targeting the binding interface or the “hormone binding” pocket of AGT.

## **Experimental procedures**

### **Recombinant protein expression**

The encoding genes for full-length human AGT and prorenin including signal peptide were amplified from I.M.A.G.E clones (Source BioScience, #4213559 for human AGT and

#5188566 for human prorenin) and inserted into the pCEP4 vector (Invitrogen). The coding sequence of spent AGT was inserted into a modified pCEP4 vector with the antitrypsin signal peptide at its N-terminus for secretion. All the constructs included a 6\*His tag at the C-terminus of the gene and were verified by DNA sequencing (Source BioScience) before being transfected transiently into HEK293 EBNA cells using polyethylenimine (PEI, linear, MW 25000, Polysciences, Inc.). Recombinant proteins were purified from concentrated serum-free expression medium by nickel affinity (HisTrap, GE Healthcare Life Sciences) and anion exchange chromatography (Hitrap Q, GE Healthcare Life Sciences) consecutively.

#### **Mutations in the crystallized AGT-N14 protein**

Three out of four potentially glycosylated asparagines in human AGT were mutated to glutamines to minimize the glycosylation heterogeneity of AGT for crystallization. Two free cysteines (Cys232 and Cys308) were replaced with serines to avoid potential aggregation.

The actual mutations in AGT-N14 were Asn137/271/295Gln and Cys232/308Ser. The same mutations were introduced to spent AGT-N14 for crystallization. A cysteine modification experiment confirmed that Cys18-Cys138 disulfide bond is properly formed within these variants (Figure S-6). All the mutations were introduced by site-directed mutagenesis using the QuickChange kit (Agilent Technologies). All the primers for molecular cloning and mutagenesis are listed in Supporting Information Table S-1.

#### **Preparation of reactive center loop-cleaved AGT**

The reactive center loop (RCL) cleaved human AGT was made by thermolysin cleavage

between Gln412-Leu413 of AGT-N14 and confirmed by SDS-PAGE (Figure S-7) and mass spectrometry. The ratio of protein/protease ratio and reaction time were optimized by incubating AGT-N14 (singly glycosylated at Asn14) with a 2-fold serial dilution of thermolysin for various times. The final digestion condition for large scale prep combined 1mg/ml full-length AGT and thermolysin with a protein/protease ratio of 3200:1 (W/W) at room temperature for 3h in a buffer containing 10mM Tris, 0.15M NaCl and 10mM CaCl<sub>2</sub>. The reaction was stopped by addition of 10mM EDTA and further purified by ion exchange chromatography before crystallization.

#### **Preparation of AGT-renin complex**

The Asp226Ala mutant of human prorenin, with one of the two active site aspartate residues mutated to Ala, was incubated with trypsin (Sigma) at an optimized 200:1 molar ratio to remove the prosegment, and then the reaction was stopped by adding 1mM phenylmethylsulfonyl fluoride (PMSF). After removal of PMSF and buffer exchange to 10mM Tris pH 7.4 and 0.15 M NaCl, the resulting inactive renin Asp226Ala was deglycosylated with peptide-N-glycosidase F (PNGase F) (NEB), at an optimized ratio of 1U PNGase F to 1µg renin. The deglycosylated renin Asp226Ala was further purified by binding to a nickel column to remove PNGaseF. The stable AGT:renin complex was made by mixing AGT-N14 and inactive renin Asp226Ala mutant at a 1:1.2 molar ratio and purified by size-exclusion chromatography using a HiLoad 16/60 Superdex 200 (GE Healthcare Life Sciences) column equilibrated with 10mM Tris pH7.4 and 0.1M NaCl. Fractions containing the complex were collected and concentrated to 8mg/ml for crystallization.

### **Crystallization, data collection and structure determination**

The diffraction quality crystals of intact, spent and RCL-cleaved AGT were grown by microseeding in 96-well sitting drop plates (300nl reservoir, 200nl 10mg/ml protein and 100nl seeds) against 80 $\mu$ l of a range of concentrations of (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and different pH buffers. The seeds were prepared using unglycosylated AGT crystals grown in 20% PEG6000, 1.0M LiCl and 0.1M Tris pH8.0. As frequently observed in previous examples of cross-seeding with non-identical proteins(40), the resulting crystals did not share the same crystal packing. A similar method was applied to grow crystals of the complex. Optimized complex crystals were obtained by equilibrating 1 $\mu$ l of 8mg/ml protein, 1.5 $\mu$ l of reservoir and 0.5 $\mu$ l seeds in sitting drop plates against 1ml of reservoir solution of 1.74M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and 0.1M Tris pH7.6. The intact and spent AGT crystals, grown in 96-well sitting drop plates, were cryo-protected by adding 0.5 $\mu$ l perfluoropolyether oil (Hampton research) to the top of the drops. The complex crystals were soaked in cryo-solutions of 2M Li<sub>2</sub>SO<sub>4</sub>, 1M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> plus 0.1M Tris pH7.6 before harvesting. All the crystals covered with cryo-solutions were flash-cooled in liquid nitrogen.

Diffraction data were collected at beamlines I04 (spent AGT), I04-1 (intact AGT, AGT:renin complex) and I02 (RCL-cleaved AGT) of the Diamond Synchrotron Light Source and processed with Mosflm(41) and Aimless(42) in the CCP4 program suite. Resolution was decided by  $CC_{1/2} > 0.5$  and  $\langle I/\sigma \rangle$  over 1 in the outer resolution shell(43, 44). The structures of intact, loop-cleaved and spent AGT were solved by molecular replacement in Phaser(45) by searching with the unglycosylated AGT structure (PDB 2WXW).

The crystals of intact and loop-cleaved AGT each contained one copy in the asymmetric unit, while the spent AGT crystal contained two copies. The complex structure was solved by molecular replacement using the unglycosylated AGT structure (PDB 2WXW), from which the N-terminal residues 1-30 had been trimmed, and renin (PDB 2BKS) as search models. One copy of the complex was present in the asymmetric unit. Manual model building was carried out in COOT(46) and further refinement was performed in Phenix.refine(47) and Refmac(48). The final models were validated using MolProbity(49) and final refinement statistics for all four structures are shown in Table 1. The carbohydrate structures were built with consideration of the correct core carbohydrate linkages(50). Torsion angles for carbohydrate linkages were validated using the program carp(51). Molecular graphics were prepared using Pymol(52) and protein:protein interactions were analyzed using PDBePISA(53).

### **Enzyme kinetics of the human renin and AGT reaction**

For steady-state kinetics, the reaction time and renin concentration were optimized to ensure product formation is linear with time and the renin concentration is well below the  $K_M$  of the system. Briefly, various concentrations of AGT mutants (eight 2-fold dilutions up to around 10\*  $K_M$ ) were incubated with 0.2nM renin at 37°C for 1h in a buffer of 10mM Tris pH7.4, 0.15M NaCl and 0.25mg/ml bovine serum albumin. The reactions were stopped by heating the sample at 98°C for 5min. The amount of released Ang I peptide was quantified by immunoassay (S-1188 kit, Peninsula Laboratories, LLC) and plotted against the substrate concentrations. The key consideration was that the measured Ang I concentrations must be within the linear range of

the standard curve. The kinetic parameters ( $V_{\max}$  and  $K_M$ ) for the cleavage of AGT by renin were fit with the standard Michaelis-Menten equation using GraphPad Prism 5, and  $k_{\text{cat}}$  was calculated as  $V_{\max}/[E]_t$ . The mean and standard deviation calculated from 3 independent experiments are presented in Table 2.

### The affinity of human AGT binding to renin

The binding kinetics for the interaction between AGT and inactivated renin were measured using a FortéBio Octet Red96 biolayer interferometry system (Menlo Park, CA, U.S.). Renin Asp226Ala was biotinylated preferentially on N-terminal  $\alpha$ -amino groups at pH 6.2 using EZ-link-NHS-PEG4-Biotin (Thermo Scientific). Such preferential labelling is achieved by using a reaction pH that is lower than the typical range used for reaction by NHS-ester reagents(54). The optimized biotinylation condition was a 1:0.8 ratio of protein to reagent at 4°C for two hours. Non-reacted NHS-PEG4-Biotin was removed by a Zeba spin desalting column (7K MWCO, Thermo Scientific). 2.5 $\mu$ g/ml biotinylated renin Asp226Ala mutant was loaded on to streptavidin biosensors (18-5019, FortéBio). A range of 2-fold dilutions of AGT mutants was prepared in 10mM Tris pH7.4, 0.15M NaCl and 1% BSA covering  $10*K_D$  to  $0.1*K_D$ . Responses were processed with the FortéBio Data Analysis 7.0 software. The kinetic association rate constant ( $k_{\text{on}}$ ) and

dissociation rate constant ( $k_{\text{off}}$ ) were generated using a 1:1 binding model by a global fit without linked  $R_{\max}$ . The equilibrium dissociation constant ( $K_D$ ) was calculated as  $k_{\text{off}}$  divided by  $k_{\text{on}}$ . For the reaction of renin and spent AGT, as the on and off rates were very fast and all the association binding curves reached equilibrium, a steady state analysis was performed to calculate  $K_D$ . Three independent assays were performed to calculate the mean and standard deviation (Table 2).

### Alkylation of free sulfhydryl groups of cysteines in AGT

5 $\mu$ l of 1mg/ml protein was reduced by 5 $\mu$ l of 10mM tris (2-carboxyethyl) phosphine (TCEP) at room temperature for 20min. Then 10 $\mu$ l of 20mM methoxypolyethylene glycol (mean molecular weight of 2,000)-maleimide (mPEG2000-mal; Sunbright ME-020MA, NOF Europe) was added to alkylate the free sulfhydryl groups of cysteines. The mixture was incubated at room temperature for 40min. An aliquot of each sample was also incubated with mPEG2000-mal without reduction by TCEP. Samples were separated by SDS-PAGE and stained with InstantBlue (Expedeon) to observe the band shift after modification. The reduced disulfide bond reacts with two mPEG2000-mal moieties, causing a 4kD shift in SDS-PAGE. Note that the two free Cys232 and Cys308 of wild-type AGT were mutated to serine in this experiment.

## Acknowledgments

We thank Diamond Light Source for access to beamlines I04 and I04-1 (proposal mx8547) that contributed to the results reported here. Assistance from Janet Deane in collecting and processing the data is gratefully acknowledged. This work was supported by a grant from the British Heart Foundation (PG/12/41/29679) and a Principal Research Fellowship awarded to RJR by the Wellcome Trust (082961/Z/07/Z). AZ was supported by the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning and by the National Natural Science Foundation of China (31370727 and 81572090). The research was facilitated by a Wellcome Trust Strategic Award (100140) to the Cambridge Institute for Medical Research. Crystal structures and diffraction data have been deposited in the Worldwide Protein Data Bank under accession codes 5m3y (intact AGT), 6i3f (AGT-renin complex), 5m3x (spent AGT) and 6i3i (RCL-cleaved AGT).

## Conflict of interest

The authors declare they have no conflicts of interest with the contents of this article.

## References

1. Fyhrquist, F., and Saijonmaa, O. (2008) Renin-angiotensin system revisited. *J. Intern. Med.* **264**, 224–36
2. Crowley, S. D., and Coffman, T. M. (2012) Recent advances involving the renin-angiotensin system. *Exp. Cell Res.* **318**, 1049–56
3. Jeunemaitre, X., Soubrier, F., Kotelevtsev, Y. V., Lifton, R. P., Williams, C. S., Charru, A., Hunt, S. C., Hopkins, P. N., Williams, R. R., Lalouel, J.-M., and Corvol, P. (1992) Molecular basis of human hypertension: Role of angiotensinogen. *Cell* **71**, 169–180
4. Ward, K., Hata, A., Jeunemaitre, X., Helin, C., Nelson, L., Namikawa, C., Farrington, P. F., Ogasawara, M., Suzumori, K., and Tomoda, S. (1993) A molecular variant of angiotensinogen associated with preeclampsia. *Nat. Genet.* **4**, 59–61
5. Inoue, I., Rohrwasser, A., Helin, C., Jeunemaitre, X., Crain, P., Bohlender, J., Lifton, R. P., Corvol, P., Ward, K., and Lalouel, J. M. (1995) A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system. *J. Biol. Chem.* **270**, 11430–6
6. Cumin, F., Le-Nguyen, D., Castro, B., Menard, J., and Corvol, P. (1987) Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates. *Biochim. Biophys. Acta* **913**, 10–9
7. Burton, J., and Quinn, T. (1988) The amino-acid residues on the C-terminal side of the cleavage

- site of angiotensinogen influence the species specificity of reaction with renin. *Biochim. Biophys. Acta* **952**, 8–12
8. Zhou, A., Carrell, R. W., Murphy, M. P., Wei, Z., Yan, Y., Stanley, P. L. D., Stein, P. E., Broughton Pipkin, F., and Read, R. J. (2010) A redox switch in angiotensinogen modulates angiotensin release. *Nature* **468**, 108–11
  9. Gimenez-Roqueplo, A. P., Célérier, J., Lucarelli, G., Corvol, P., and Jeunemaitre, X. (1998) Role of N-glycosylation in human angiotensinogen. *J. Biol. Chem.* **273**, 21232–8
  10. Inui, Y., Orihashi, T., Okada, E., Nakagawa, T., Ebihara, A., and Suzuki, F. (1998) Effects of Glycosylation of the Residue at Position 14 in Ovine Angiotensinogen on the Human Renin Reaction. *Biosci. Biotechnol. Biochem.* **62**, 1612–1614
  11. Rahuel, J., Priestle, J. P., and Grütter, M. G. (1991) The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. *J. Struct. Biol.* **107**, 227–36
  12. Dhanaraj, V., Dealwis, C. G., Frazao, C., Badasso, M., Sibanda, B. L., Tickle, I. J., Cooper, J. B., Driessen, H. P., Newman, M., and Aguilar, C. (1992) X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. *Nature* **357**, 466–72
  13. Brás, N. F., Ramos, M. J., and Fernandes, P. A. (2012) The catalytic mechanism of mouse renin studied with QM/MM calculations. *Phys. Chem. Chem. Phys.* **14**, 12605–13
  14. Nabi, A. H., Uddin, M. N., Nakagawa, T., Orihashi, T., Ebihara, A., Iwasawa, A., Nakamura, Y., and Suzuki, F. (2005) Roles of His9 (P2 subsite) and His13 (P3' subsite) in angiotensinogen for catalytic reaction of renin. *Int. J. Mol. Med.* **16**, 103–7
  15. Iwata, H., Nakagawa, T., Yosgioka, Y., Kagei, K., Imada, K., Nakane, C., Fujita, H., Suzuki, F., and Nakamura, Y. (2008) The coexistence of Ser84 in renin and His13 in angiotensinogen brings a pH profile of two separate peaks to the reaction of human renin and sheep angiotensinogen. *Biosci. Biotechnol. Biochem.* **72**, 179–185
  16. Andreeva, N. S., and Rumsh, L. D. (2001) Analysis of crystal structures of aspartic proteinases: On the role of amino acid residues adjacent to the catalytic site of pepsin-like enzymes. *Protein Sci.* **10**, 2439–2450
  17. Schechter, I., and Berger, A. (1968) On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. *Biochem. Biophys. Res. Commun.* **32**, 898–902
  18. Ganten, D., Wagner, J., Zeh, K., Bader, M., Michel, J. B., Paul, M., Zimmermann, F., Ruf, P., Hilgenfeldt, U., and Ganten, U. (1992) Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. *Proc. Natl. Acad. Sci. U. S. A.* **89**, 7806–

19. Fukamizu, A., Sugimura, K., Takimoto, E., Sugiyama, F., Seo, M. S., Takahashi, S., Hatae, T., Kajiwara, N., Yagami, K., and Murakami, K. (1993) Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. *J. Biol. Chem.* **268**, 11617–21
20. Takahashi, S., Fukamizu, A., Hasegawa, T., Yokoyama, M., Nomura, T., Katsuki, M., and Murakami, K. (1991) Expression of the human angiotensinogen gene in transgenic mice and transfected cells. *Biochem. Biophys. Res. Commun.* **180**, 1103–9
21. Genain, C., Bouhnik, J., Tewksbury, D., Corvol, P., and Menard, J. (1984) Characterization of plasma and cerebrospinal fluid human angiotensinogen and des-angiotensin I-angiotensinogen by direct radioimmunoassay. *J. Clin. Endocrinol. Metab.* **59**, 478–84
22. Barrett, J. D., Eggena, P., Hidaka, H., and Sambhi, M. P. (1979) In vitro inhibition of renin by human des-angiotensin I renin substrate. *J. Clin. Endocrinol. Metab.* **48**, 96–100
23. Zhou, A., Wei, Z., Read, R. J., and Carrell, R. W. (2006) Structural mechanism for the carriage and release of thyroxine in the blood. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 13321–6
24. Celerier, J., Cruz, A., Lamande, N., Gasc, J., and Corvol, P. (2002) Angiotensinogen and its cleaved derivatives inhibit angiogenesis. *Hypertension* **39**, 224–228
25. Lu, H., Wu, C., Howatt, D. A., Balakrishnan, A., Moorlegghen, J. J., Chen, X., Zhao, M., Graham, M. J., Mullick, A. E., Crooke, R. M., Feldman, D. L., Cassis, L. A., Vander Kooi, C. W., and Daugherty, A. (2016) Angiotensinogen exerts effects independent of angiotensin II. *Arterioscler. Thromb. Vasc. Biol.* **36**, 256–265
26. Hatae, T., Takimoto, E., Murakami, K., and Fukamizu, A. (1994) Comparative studies on species-specific reactivity between renin and angiotensinogen. *Mol. Cell. Biochem.* **131**, 43–7
27. Qi, X., Loiseau, F., Chan, W. L., Yahui, Y., Wei, Z., Milroy, L.-G., Myers, R. M., Ley, S. V., Read, R. J., Carrell, R. W., and Zhou, A. (2011) Allosteric modulation of hormone release from thyroxine and corticosteroid-binding globulins. *J. Biol. Chem.* **286**, 16163–16173
28. Zhou, A., Wei, Z., Stanley, P. L. D., Read, R. J., Stein, P. E., and Carrell, R. W. (2008) The S-to-R transition of corticosteroid-binding globulin and the mechanism of hormone release. *J. Mol. Biol.* **380**, 244–51
29. Stein, P. E., Tewkesbury, D. A., and Carrell, R. W. (1989) Ovalbumin and angiotensinogen lack serpin S-R conformational change. *Biochem. J.* **262**, 103–7
30. Fournier, D., Luft, F. C., Bader, M., Ganten, D., and Andrade-Navarro, M. A. (2012) Emergence and evolution of the renin-angiotensin-aldosterone system. *J. Mol. Med. (Berl)*. **90**, 495–508

31. Wang, Y., and Ragg, H. (2011) An unexpected link between angiotensinogen and thrombin. *FEBS Lett.* **585**, 2395–9
32. Wei, H., Cai, H., Wu, J., Wei, Z., Zhang, F., Huang, X., Ma, L., Feng, L., Zhang, R., Wang, Y., Ragg, H., Zheng, Y., and Zhou, A. (2016) Heparin binds lamprey angiotensinogen and promotes thrombin inhibition through a template mechanism. *J. Biol. Chem.*, jbc.M116.725895
33. Mangan, M. S. J., Bird, C. H., Kaiserman, D., Matthews, A. Y., Hitchen, C., Steer, D. L., Thompson, P. E., and Bird, P. I. (2016) A Novel Serpin Regulatory Mechanism: SerpinB9 is reversibly inhibited by vicinal disulfide bond formation in the reactive center loop. *J. Biol. Chem.* **291**, 3626–38
34. Rahgozar, S., Amirian, T., Qi, M., Shahshahan, Z., Entezar-E-Ghaem, M., Tehrani, H. G., Miroliaei, M., Krills, S. A., and Giannakopoulos, B. (2015) Improved assay for quantifying a redox form of angiotensinogen as a biomarker for pre-eclampsia : a case-control study. *PLoS One*, 1–12
35. Pol-Fachin, L., Franco Becker, C., Almeida Guimarães, J., and Verli, H. (2011) Effects of glycosylation on heparin binding and antithrombin activation by heparin. *Proteins Struct. Funct. Bioinforma.* **79**, 2735–2745
36. Sumer-Bayraktar, Z., Grant, O. C., Venkatakrishnan, V., Woods, R. J., Packer, N. H., and Thaysen-Andersen, M. (2016) Asn347 Glycosylation of Corticosteroid-binding Globulin Fine-tunes the Host Immune Response by Modulating Proteolysis by *Pseudomonas aeruginosa* and Neutrophil Elastase. *J. Biol. Chem.* **291**, 17727–42
37. Rudd, P. M., Woods, R. J., Wormald, M. R., Opdenakker, G., Downing, A. K., Campbell, I. D., and Dwek, R. A. (1995) The effects of variable glycosylation on the functional activities of ribonuclease, plasminogen and tissue plasminogen activator. *Biochim. Biophys. Acta (BBA)/Protein Struct. Mol.* **1248**, 1–10
38. Rong, P., Campbell, D. J., and Skinner, S. L. (2003) Hypertension in the (mRen-2)<sup>27</sup> rat is not explained by enhanced kinetics of transgenic Ren-2 renin. *Hypertension* **42**, 523–7
39. Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O'Donnell-Luria, A. H., Ware, J. S., Hill, A. J., Cummings, B. B., Tukiainen, T., Birnbaum, D. P., Kosmicki, J. A., Duncan, L. E., Estrada, K., Zhao, F., Zou, J., Pierce-Hoffman, E., Berghout, J., Cooper, D. N., Deflaux, N., DePristo, M., Do, R., Flannick, J., Fromer, M., Gauthier, L., Goldstein, J., Gupta, N., Howrigan, D., Kiezun, A., Kurki, M. I., Moonshine, A. L., Natarajan, P., Orozco, L., Peloso, G. M., Poplin, R., Rivas, M. A., Ruano-Rubio, V., Rose, S. A., Ruderfer, D. M., Shakir, K., Stenson, P. D., Stevens, C., Thomas, B. P., Tiao, G., Tusie-Luna, M. T., Weisburd, B., Won, H.-H., Yu, D., Altshuler, D. M., Ardissino, D., Boehnke, M., Danesh, J., Donnelly, S., Elosua, R., Florez, J. C., Gabriel, S. B., Getz, G., Glatt, S. J., Hultman, C. M., Kathiresan, S., Laakso, M., McCarroll, S., McCarthy, M. I., McGovern, D., McPherson, R., Neale, B. M., Palotie, A., Purcell, S. M., Saleheen, D., Scharf, J. M., Sklar, P., Sullivan, P. F., Tuomilehto, J., Tsuang, M. T., Watkins, H. C., Wilson, J. G., Daly, M. J., and MacArthur, D. G.

- (2016) Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291
40. D'Arcy, A., Villard, F., and Marsh, M. (2007) An automated microseed matrix-screening method for protein crystallization. *Acta Crystallogr. D. Biol. Crystallogr.* **63**, 550–4
41. Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., and Leslie, A. G. W. (2011) iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. *Acta Crystallogr. D. Biol. Crystallogr.* **67**, 271–81
42. Evans, P. R. (2011) An introduction to data reduction: space-group determination, scaling and intensity statistics. *Acta Crystallogr. D. Biol. Crystallogr.* **67**, 282–92
43. Evans, P. R., and Murshudov, G. N. (2013) How good are my data and what is the resolution? *Acta Crystallogr. Sect. D Biol. Crystallogr.* **69**, 1204–1214
44. Karplus, P. A., and Diederichs, K. (2012) Linking crystallographic model and data quality. *Science* **336**, 1030–1033
45. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674
46. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D. Biol. Crystallogr.* **66**, 486–501
47. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D. Biol. Crystallogr.* **D66**, 213–21
48. Winn, M. D., Isupov, M. N., and Murshudov, G. N. (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement. *Acta Crystallogr. D. Biol. Crystallogr.* **57**, 122–33
49. Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr. D. Biol. Crystallogr.* **66**, 12–21
50. Lütteke, T. (2009) Analysis and validation of carbohydrate three-dimensional structures. *Acta Crystallogr. D. Biol. Crystallogr.* **65**, 156–68
51. Lütteke, T., Frank, M., and von der Lieth, C.-W. (2005) Carbohydrate Structure Suite (CSS): analysis of carbohydrate 3D structures derived from the PDB. *Nucleic Acids Res.* **33**, D242–6
52. Pymol (2010) The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.

53. Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. *J. Mol. Biol.* **372**, 774–97
54. Sélo, I., Négroni, L., Créminon, C., Grassi, J., and Wal, J. M. (1996) Preferential labeling of  $\alpha$ -amino N-terminal groups in peptides by biotin: application to the detection of specific anti-peptide antibodies by enzyme immunoassays. *J. Immunol. Methods* **199**, 127–138

**Table 1. Data collection and refinement statistics.**

	Intact human AGT	AGT-Renin complex	Spent AGT	RCL-cleaved AGT
Residue ranges*	34-485	AGT: 34-485 Renin: 67-406	44-485	34-485
<b>Data collection</b>				
Synchrotron stations	DLS I04-1	DLS I04-1	DLS I04	DLS I02
Space group	P4 <sub>1</sub>	P6 <sub>3</sub> 22	P2	P4 <sub>1</sub>
a,b,c; Å	71.35, 71.35, 125.3	124.1, 124.1, 260.9	86.3, 41.04, 129.95	80.14, 80.14, 117.13
$\alpha, \beta, \gamma; ^\circ$	90, 90, 90	90, 90, 120	90, 107.82, 90	90, 90, 90
Resolution, Å**	46.8-2.3 (2.38-2.3)	62.06-2.55 (2.65-2.55)	43.44-2.63 (2.7-2.63)	66.14-2.97 (3.05-2.97)
R <sub>merge</sub> **	0.057 (0.702)	0.209 (1.251)	0.139 (0.801)	0.214 (1.282)
$\langle I/\sigma(I) \rangle$ **	16.6 (2.3)	10.2 (2.1)	6.9 (1.3)	6.5 (1.4)
CC <sub>1/2</sub> **	0.999 (0.511)	0.998 (0.674)	0.987 (0.534)	0.987 (0.530)
Completeness, %**	99.9 (99.9)	100 (100)	99.3 (99.3)	100 (100)
Redundancy**	6.5 (5.4)	12.7 (12.9)	3.3 (3.3)	6.7 (7.1)
<b>Refinement</b>				
R <sub>work</sub> /R <sub>free</sub>	0.178/0.196	0.208/0.234	0.241/0.284	0.219/0.237
No. of unique reflections**	27786 (2704)	39584 (4393)	26230 (1930)	14563 (1106)
No. of atoms (non H)	3328	6136	5923	3336
Average B-factors	63.5	40.4	42.5	68.7
<b>RMS deviations</b>				
Bond lengths Å	0.003	0.002	0.003	0.003
Bond angles, °	0.613	1.192	0.707	0.754
Ramachandran favored region, %	96.8	97.6	97.7	96.4
Ramachandran outliers, %	0	0	0	0
MolProbity score†	1.54 (99%)	0.85(100%)	1.28 (100%)	1.27 (100%)
PDB code	5M3Y	6I3F	5M3X	6I3I

\*corresponding to UniProt entry P01019 for AGT and P00797 for renin.


\*\*Values in parentheses are for highest-resolution shell.

†100<sup>th</sup> percentile is the best among structures of comparable resolutions. 0<sup>th</sup> percentile is the worst.

**Table 2. Binding affinity and kinetic parameters of human renin/angiotensinogen interaction.**


AGT	$k_{on}$ (1/Ms)	$k_{off}$ (1/s)	$K_D$ (nM)	$k_{cat}$ (s <sup>-1</sup> )	$K_M$ ( $\mu$ M)	$k_{cat}/K_M$ (s <sup>-1</sup> $\mu$ m <sup>-1</sup> )
Wild-type	2.15 ( $\pm$ 0.36) $\times 10^4$	4.37 ( $\pm$ 1.2) $\times 10^{-4}$	20.3 $\pm$ 2.2 (100%)	0.20 $\pm$ 0.01	0.76 $\pm$ 0.08	0.25 $\pm$ 0.01 (100%)
N331D	3.21 ( $\pm$ 0.81) $\times 10^3$	2.96 ( $\pm$ 0.88) $\times 10^{-4}$	91.5 $\pm$ 5.3 (456%)	0.14 $\pm$ 0.01	2.56 $\pm$ 0.37	0.05 $\pm$ 0.01 (21%)
R83H	1.40 ( $\pm$ 0.27) $\times 10^4$	6.06 ( $\pm$ 0.37) $\times 10^{-4}$	44.6 $\pm$ 11.1 (222%)	0.20 $\pm$ 0.03	1.42 $\pm$ 0.12	0.14 $\pm$ 0.01 (54%)
N334T	1.50 ( $\pm$ 0.01) $\times 10^4$	4.18 ( $\pm$ 0.56) $\times 10^{-4}$	27.9 $\pm$ 3.7 (138%)	0.16 $\pm$ 0.01	0.76 $\pm$ 0.05	0.22 $\pm$ 0.01 (84%)
N4	7.46 ( $\pm$ 1.57) $\times 10^4$	8.61 ( $\pm$ 0.49) $\times 10^{-5}$	1.2 $\pm$ 0.2 (5.9%)	0.44 $\pm$ 0.02	0.67 $\pm$ 0.10	0.65 $\pm$ 0.08 (255%)
N14Q	3.61 ( $\pm$ 0.04) $\times 10^4$	2.09 ( $\pm$ 0.39) $\times 10^{-4}$	5.8 $\pm$ 1.1 (28.9%)	0.35 $\pm$ 0.01	0.56 $\pm$ 0.02	0.64 $\pm$ 0.03 (252%)

Bio-layer interferometry was used to measure the binding kinetic constants ( $k_{on}$ ,  $k_{off}$  and  $K_D$ ) between the inactivated human renin mutant (D226A) and human AGT in both wild-type and mutant forms (as indicated on the left column; N4 represents the quadruple glycosylation mutant N14/137/271/295Q). The enzymatic kinetic parameters ( $K_M$ ,  $k_{cat}$  and  $k_{cat}/K_M$ ) for the cleavage efficiency by wild-type human renin of human AGT mutants (the same panel of AGT mutants as the binding assay) were measured by quantifying the released Ang I. All the proteins were expressed in HEK293EBNA cells. The mean and standard deviation were computed from three independent experiments.




**Figure 1. The crystal structure of human glycosylated AGT.** (A) The N-terminal tail sequence of AGT, indicating the renin and ACE cleavage sites, the glycosylation site and the conserved disulfide bond. (B) The structure of AGT is shown as a cartoon. The serpin template is in grey and helix A (hA) is in marine with the A-sheet (sA) in light blue and the disordered reactive center loop (RCL) in red dashes. The Ang I segment is in magenta and the following amino-tail is in green with the scissile bond shown as magenta and green spheres. Cysteine 18 in the amino tail forms a disulfide bond with Cysteine 138 of the CD-loop (brown). The glycan attached to Asn14 is shown as green sticks. The segment from Glu20-Pro29 (dashed, pale green) is disordered in the structure and modelled for illustration. Helix H (hH) is in red and helix G (hG) is in wheat color. (C) Surface representation of the main body of AGT, with the extra N-terminus (1-63) shown in cartoon representation. The Ang I peptide is mainly stabilized by hydrophobic interactions with the main body. Residues I5, F8, L10, V11 and I12 (shown as sticks) form hydrophobic interactions with residues in the CD-loop (V131, P132 and W133 as brown surface), helix A (L68, M72, L76 and F79 as marine surface) and helix D (hD, L142 and V147 as cyan surface). The scissile bond (L10-V11) is buried in the hydrophobic cavity.






**Figure 3. Interactions inside the renin active cleft.** (A) Renin residues are shown as grey and the AGT peptide is in magenta. D38 in renin is hydrogen-bonded to the carbonyl oxygen of the scissile bond and a water (W1) that is also within hydrogen-bond range to the other mutated aspartic acid (A226). The conserved hydrogen bond network W45-Y83-water (W2)-S41-D38 is present. (B) H9 in AGT is hydrogen-bonded to S233. H9 also connects to H13 through a bridging water (W3). S84 in the N-flap forms a hydrogen bond with a water (W4), which connects to the carbonyl oxygen of H9. (C) Binding subsites in the renin active cleft. Subsite S3 (P118, F119, L121, A122 and F124 of renin) accommodates F8; S1 (F119, F124, V127, V36 and Y83) accommodates L10; S1' (L224 and I305) accommodates V11; and S2' (I137, L81 and Y83) accommodates I12. The N-flap of renin is shown as yellow and the C-flap is in purple. (D) The N-flap of renin (yellow) in the AGT-renin complex adopts an 'open' position with a movement of 4.8 Å compared to its conformation in the unbound renin (cyan, PDB 1BBS). There is no such conformational change when a decapeptide substrate (corresponding to residues 4-14 of rat AGT) is bound to mouse submaxillary renin (pink, PDB entry 1SMR). The N-terminal residues 1-10 of the AGT peptide are in magenta and the following residues 11-15 and the glycan are shown as green.




**Figure 4. Interactions between renin and angiotensinogen in the complex.** (A) An opened-up cartoon view of the interface (with the renin moiety rotated 180° around the y axis) illustrating the hydrophobic interactions and hydrogen-bonded residues (sticks). (B) An opened-up surface representation highlights hydrophobic interactions at the interface. (C) Cartoon view of the interface, with hydrogen bonds shown as red dashes between interacting residues (sticks). Renin, on the left, is shown as grey with interacting residues in yellow. AGT, on the right, is shown using the colors defined for Figures 1. (D) Residues involved in hydrogen-bonding interactions are listed, along with the identities of corresponding residues in AGT from other species. The plot shows that cleavage efficiency is reduced when N331 or R83 of human AGT are replaced by equivalent residues from rat or mouse AGT respectively. The detailed kinetic constants are listed in Table 2.



**Figure 5. Conformational changes of angiotensinogen upon renin interaction.** Side views of AGT alone (A) and from the complex with renin (B) illustrate the substantial movement of the N-terminus of AGT into the renin active cleft. The scissile bond (shown as spheres) moves 18.6 Å during the complex formation. The color coding and abbreviations are the same as in Figure 1. (C) Superposed structures of native AGT and AGT from the complex with renin show significant structural rearrangement of helices H, A, I, and J (hH, hA, hI, and hJ) of AGT upon renin binding. Native AGT is shown as grey with a cyan helix H and AGT in the complex is color coded as AGT in Figure 1. Helix H is completely unwound with the C $\alpha$  atom of N331 (shown as cyan stick in native AGT and red stick in AGT complexed with renin) shifting more than 6Å to interact with Y60 of renin. Helix A is extended by two turns with the side chain of W92 (shown as magenta stick in native AGT and marine stick in AGT complexed with renin) at the tip of helix A being flipped out. (D) Superposed structures of native (grey) and spent AGT (same color coding as AGT in Figure 1) show that spent AGT largely resembles native AGT, but with differences in helix H and the CD-loop (blue in spent AGT). Helix H of spent AGT

is completely disordered



**Figure 6. The insertion of the N-terminal peptide into the hormone binding pocket.** (A) Renin binding results in the N-terminus of AGT being inserted into the hormone binding pocket and in unwinding of helix H. The side chain of Arg2 is largely buried and forms stabilizing interactions with Gln300. Val3 and Tyr4 also form hydrophobic interactions with surrounding residues. (B) There is clear electron density for all the residues in the N-terminus (grey mesh, 2mFo-DFc map, contoured at 1.0 sigma, including density within 1.6 Å of atoms in the N-terminus). (C) A similarly located pocket is used to bind thyroxine (T4, spheres) in thyroxine binding globulin (TBG).